HeartFlow’s FFRct software is designed to aid in the diagnosis and treatment of patients with suspected coronary artery disease, providing insight into the extent of the CAD and the impact it is having on blood flow to the heart.
“GE has collaborated with HeartFlow over the last five years, and this agreement reinforces our joint commitment to patients worldwide. Along with our industry-leading cardiac CT systems and clinical applications, GE can now offer HeartFlow FFRct as an option for healthcare providers who strive to deliver the highest standards in clinical care while reducing costs,” GE global premium CT biz GM Scott Schubert said in a prepared statement.
The collaborative deal will initially focus on the US market, with plans to expand into other markets in the future, the companies said. Initial integration will include GE’s Revolution line of CT scanners, the CardioGraphe cardiovascular CT scanner and GE’s AW advanced clinical applications.
“This agreement with GE will help bring our game-changing non-invasive technology into the mainstream of cardiac care at thousands of hospitals that are already using state-of-the-art CT systems from GE, which provide exceptional image quality. By collaborating, we can ensure that HeartFlow FFRct can be easily integrated into existing CAD protocols and more readily transform the care of patients with suspected and potentially life-threatening CAD,” HeartFlow prez & CEO Dr. John Stevens said in a press release.
Yesterday, HeartFlow said it won a new set of category III Current Procedural Terminology codes from the American medical Association for its FFRct fractional flow reserve technology.